Open AccessIbrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
Author(s) -
Januario E. Castro,
Paula A. Lengerke-Diaz,
Juliana Vélez Luján,
Michael Y. Choi,
Eider Moreno-Cortes,
José Vicente Forero-Forero,
Juan Esteban García-Robledo,
C Jacobs,
Colin McCarthy,
Alaina Heinen,
Carlos I. Amaya-Chanaga,
Thomas J. Kipps
Publication year - 2022
Publication title -
advances in hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.371
H-Index - 31
eISSN - 1687-9112
pISSN - 1687-9104
DOI - 10.1155/2022/4450824
Subject(s) - ibrutinib , medicine , obinutuzumab , discontinuation , oncology , chronic lymphocytic leukemia , leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom